IBIO INC (IBIO) Stock Price, Quote, News and Overview
NASDAQ:IBIO - Nasdaq - US4510337086 - Common Stock - Currency: USD
IBIO Quote, Performance and Key Statistics
0.8208
+0.02 (+2.69%)
The current stock price of IBIO is 0.8208 USD. In the past month the price increased by 17.26%. In the past year, price decreased by -62.52%.
IBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Related stock screener links
About IBIO
Company Profile
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in Bryan, Texas and currently employs 16 full-time employees. The company went IPO on 2008-08-18. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Company Info
IBIO INC
8800 HSC Pkwy
Bryan TEXAS 77807 US
CEO: Thomas F. Isett
Employees: 16
Phone: 19794460027
IBIO INC / IBIO FAQ
What is the stock price of IBIO INC today?
The current stock price of IBIO is 0.8208 USD. The price increased by 2.69% in the last trading session.
What is the ticker symbol for IBIO INC stock?
The exchange symbol of IBIO INC is IBIO and it is listed on the Nasdaq exchange.
On which exchange is IBIO stock listed?
IBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IBIO INC stock?
8 analysts have analysed IBIO and the average price target is 4.96 USD. This implies a price increase of 504.78% is expected in the next year compared to the current price of 0.8208. Check the IBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IBIO INC worth?
IBIO INC (IBIO) has a market capitalization of 8.10M USD. This makes IBIO a Nano Cap stock.
How many employees does IBIO INC have?
IBIO INC (IBIO) currently has 16 employees.
What are the support and resistance levels for IBIO INC (IBIO) stock?
IBIO INC (IBIO) has a support level at 0.72. Check the full technical report for a detailed analysis of IBIO support and resistance levels.
Is IBIO INC (IBIO) expected to grow?
The Revenue of IBIO INC (IBIO) is expected to grow by 1100% in the next year. Check the estimates tab for more information on the IBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IBIO INC (IBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IBIO, evaluating the profitability, health, valuation and growth aspects
- IBIO INC (IBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IBIO INC (IBIO) Sales and EPS estimates to see what analysts future expectations are.
- IBIO INC (IBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IBIO INC (IBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- IBIO INC (IBIO) Stock Chart to make your own analysis
- IBIO INC (IBIO) Latest news and press-releases to stay up to date.
Does IBIO INC (IBIO) stock pay dividends?
IBIO does not pay a dividend.
When does IBIO INC (IBIO) report earnings?
IBIO INC (IBIO) will report earnings on 2025-09-18, after the market close.
What is the Price/Earnings (PE) ratio of IBIO INC (IBIO)?
IBIO INC (IBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.33).
What is the Short Interest ratio of IBIO INC (IBIO) stock?
The outstanding short interest for IBIO INC (IBIO) is 19.01% of its float. Check the ownership tab for more information on the IBIO short interest.
IBIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IBIO. When comparing the yearly performance of all stocks, IBIO is a bad performer in the overall market: 98.22% of all stocks are doing better.
IBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IBIO. IBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IBIO Financial Highlights
Over the last trailing twelve months IBIO reported a non-GAAP Earnings per Share(EPS) of -2.33. The EPS increased by 86.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.89% | ||
| ROE | -184.45% | ||
| Debt/Equity | 0 |
IBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to IBIO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 78.54% and a revenue growth 1100% for IBIO